CMT Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-180,300
Closed -$16M 11
2017
Q3
$16M Buy
180,300
+128,400
+247% +$9.77M 0.77% 45
2017
Q2
$3.76M Sell
51,900
-9,600
-16% -$645K 0.25% 90
2017
Q1
$4.01M Sell
61,500
-77,600
-56% -$4.88M 0.34% 76
2016
Q4
$8.71M Buy
139,100
+93,700
+206% +$5.72M 0.41% 66
2016
Q3
$2.86M Sell
45,400
-1,800
-4% -$117K 0.13% 113
2016
Q2
$2.92M Buy
47,200
+7,200
+18% +$439K 0.15% 105
2016
Q1
$2.29M Sell
40,000
-18,900
-32% -$1.05M 0.15% 115
2015
Q4
$3.49M Sell
58,900
-74,300
-56% -$4.28M 0.18% 110
2015
Q3
$7.25M Buy
133,200
+106,700
+403% +$6.95M 0.41% 71
2015
Q2
$1.78M Buy
26,500
+7,900
+42% +$516K 0.11% 136
2015
Q1
$1.09M Buy
+18,600
New +$1.12M 0.08% 142

Other funds holding ABBV

CMT Asset Management's ABBV Position: Q4 2017 in Review

CMT Asset Management sold out of AbbVie (ABBV) in Q4 2017, closing a stake of 5,898 shares — an estimated $524K sold.

CMT Asset Management first reported a position in ABBV in Q1 2015 and held it in 8 quarters. The position peaked at $2.78M in Q3 2015. 2,000 funds tracked by Wall St. Rank hold ABBV as of Q4 2017.

  • CMT Asset Management reported no remaining AbbVie position as of Q4 2017 after selling out during the quarter.
  • CMT Asset Management sold 5,898 AbbVie shares in Q4 2017, an estimated $524K.
  • CMT Asset Management first reported a position in AbbVie in Q1 2015 and held it in 8 quarters.
  • CMT Asset Management's AbbVie position peaked at $2.78M in Q3 2015.
  • 2,000 funds tracked by Wall St. Rank held AbbVie as of Q4 2017.

Based on CMT Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.